BioNTech AG. (12/21/17). "Press Release: BioNTech to Present at 36th Annual J.P. Morgan Healthcare Conference". Mainz.

	Region	San Francisco, CA
	Country	United States (USA)
	Organisation	BioNTech AG
	Today	BioNTech SE (Nasdaq: BNTX)
	Group	BioNTech (Group)
	Organisation 2	ICR Inc.
	Group	ICR (Group)
	Product	J.P. Morgan 36th Annual Healthcare Conference 2018 San Francisco
	Product 2	mRNA-based vaccine
	Index term	BioNTech–JPMorgan Chase: investor conference, 201801 supply service BioNTech presents at JP Morgan Healthcare Conference 2018
	Index term 2	BioNTech–ICR: public relations, 201712 service existent by ICR Healthcare in US
	Person	Marett, Sean (BioNTech 201506 COO before Evotec)
	Person 2	Buth, Ines-Regina (akampion 200901 before Micromet Head Investor Relations before Lion Bioscience)

BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that Sean Marett, COO of BioNTech, will be presenting at the 36th Annual J.P. Morgan Healthcare Conference that is being held in San Francisco, CA from January 8-11, 2018. The Company’s presentation is scheduled for Tuesday, January 9 at 9:00 AM Pacific Standard Time.

Mr. Marett will provide an overview of the Company´s strategy as well as an update on its development programs, including its expanding clinical pipeline, in-house manufacturing capabilities, and a summary of human clinical data recently published in Nature publication on its neo-epitope based individualized mRNA cancer immunotherapeutic.

For more information, please contact:

General Inquiries:

BioNTech AG
Regina Jehle
Tel: +49 6131 9084 1273
Email: Regina.Jehle@biontech.de

US Media & Investor Inquiries:

ICR Healthcare
James Heins / Stephanie Carrington
Tel: +1 203 682 8251
Tel: +1 646 277 1282
Email: James.Heins@icrinc.com
Email: Stephanie.Carrington@icrinc.com

International Media & Investor Inquiries:

akampion
Dr. Ludger Wess / Ines-Regina Buth
Tel: +49 40 8816 5964
Tel: +49 30 2363 2768
Email: info@akampion.com

About BioNTech AG

BioNTech is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The Company combines all building blocks for individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators. BioNTech’s approach is validated by five top-tier corporate partnerships with Genentech, a member of the Roche Group, Genmab, Eli Lilly and Company, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech’s financial shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder.

More information about BioNTech is available at www.biontech.de.

Record changed: 2018-01-09